FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2364314275> ?p ?o ?g. }

• W2364314275 endingPage "6632" @default.
• W2364314275 startingPage "6627" @default.
• W2364314275 abstract "Background: We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype. Materials and Methods: From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis. All patients were treated with decitabine alone (<TEX>$20mg/m^2$</TEX> daily for 5 days) or combination AAG chemotherapy (Acla 20mg qod*4d, Ara-C <TEX>$10mg/m^2$</TEX> q12h*7d, G-CSF <TEX>$300{mu}g$</TEX> qd, the dose of G-CSF adjusted to the amount in blood routinely). Results: In 35 patients, 15 exhibited a complete response (CR), and 6 a partial response (PR), the overall response rate (CR+PR) being 60% (21 of 35). Median disease-free survival was 18 months and overall survival was 14 months. In the 15 MDS patients with a complex karyotype, the CR rate was 53.3% (8 of 15); in 20 AML patients with complex karyotype, the overall response rate was 65% (13 of 20). The response rate of decitabine alone (22 cases) was 56.5% (13 of 22), while in the combination chemotherapy group (13 cases), the effective rate was 61.5% (8 of 13)(P>0.05). There are 15 patients with chromosome 7 aberration, after treatment with decitabine, 7 CR, 3 PR, overall response rate was 66.7% (10 of 15). Of 18 patients with 3 to 5 kinds of chromosomal abnormalities, 66.7% demonstrated a response; of 17 with more than 5 chromosomal abnormalities, 52.9% had a response. In the total of 35 patients, with one course (23 patients) and <TEX>${geq}$</TEX>two courses (12 patients), the overall response rate was 40.9% and 92.3% (P<0.05). Grade III to IV hematological toxicity was observed in 27 cases (75%). Grade III to IV infections were clinically documented in 7 (20%). Grades I to II non-hematological toxicity were infections (18 patients), haematuria (2 patients), and bleeding (3 patients). With follow-up until September 2013, 7 patients were surviving, 18 had died and 10 were lost to follow-up. In the 6 cases who underwent allogeneic hematopoietic stem cell transplantation (HSCT) all were still relapse-free survivors. Conclusions: Decitabine alone or combination with AAG can improve outcome of AML/MDS with a complex karyotype, there being no significant difference decitabine in inducing remission rates in patients with different karyotype. Increasing the number of courses can improve efficiency. This approach with fewer treatment side effects in patients with a better tolerance should be employed in order to create an improved subsequent chance for HSCT." @default.
• W2364314275 created "2016-06-24" @default.
• W2364314275 creator A5005355639 @default.
• W2364314275 creator A5006739024 @default.
• W2364314275 creator A5011087252 @default.
• W2364314275 creator A5022501218 @default.
• W2364314275 creator A5028474331 @default.
• W2364314275 creator A5030108757 @default.
• W2364314275 creator A5042921774 @default.
• W2364314275 creator A5049169191 @default.
• W2364314275 creator A5060335470 @default.
• W2364314275 creator A5068951778 @default.
• W2364314275 creator A5071443000 @default.
• W2364314275 creator A5076246718 @default.
• W2364314275 date "2015-10-06" @default.
• W2364314275 modified "2023-10-12" @default.
• W2364314275 title "Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively" @default.
• W2364314275 cites W1492609361 @default.
• W2364314275 cites W1974512900 @default.
• W2364314275 cites W1981978962 @default.
• W2364314275 cites W1995726388 @default.
• W2364314275 cites W1996917824 @default.
• W2364314275 cites W2013217000 @default.
• W2364314275 cites W2022240113 @default.
• W2364314275 cites W2054460399 @default.
• W2364314275 cites W2078253597 @default.
• W2364314275 cites W2094030526 @default.
• W2364314275 cites W2106082819 @default.
• W2364314275 cites W2119626196 @default.
• W2364314275 cites W2129510594 @default.
• W2364314275 cites W2148047805 @default.
• W2364314275 cites W2169007954 @default.
• W2364314275 cites W2281282082 @default.
• W2364314275 cites W2147083172 @default.
• W2364314275 doi "https://doi.org/10.7314/apjcp.2015.16.15.6627" @default.
• W2364314275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26434886" @default.
• W2364314275 hasPublicationYear "2015" @default.
• W2364314275 type Work @default.
• W2364314275 sameAs 2364314275 @default.
• W2364314275 citedByCount "9" @default.
• W2364314275 countsByYear W23643142752016 @default.
• W2364314275 countsByYear W23643142752017 @default.
• W2364314275 countsByYear W23643142752019 @default.
• W2364314275 countsByYear W23643142752021 @default.
• W2364314275 crossrefType "journal-article" @default.
• W2364314275 hasAuthorship W2364314275A5005355639 @default.
• W2364314275 hasAuthorship W2364314275A5006739024 @default.
• W2364314275 hasAuthorship W2364314275A5011087252 @default.
• W2364314275 hasAuthorship W2364314275A5022501218 @default.
• W2364314275 hasAuthorship W2364314275A5028474331 @default.
• W2364314275 hasAuthorship W2364314275A5030108757 @default.
• W2364314275 hasAuthorship W2364314275A5042921774 @default.
• W2364314275 hasAuthorship W2364314275A5049169191 @default.
• W2364314275 hasAuthorship W2364314275A5060335470 @default.
• W2364314275 hasAuthorship W2364314275A5068951778 @default.
• W2364314275 hasAuthorship W2364314275A5071443000 @default.
• W2364314275 hasAuthorship W2364314275A5076246718 @default.
• W2364314275 hasBestOaLocation W23643142751 @default.
• W2364314275 hasConcept C104317684 @default.
• W2364314275 hasConcept C126322002 @default.
• W2364314275 hasConcept C143998085 @default.
• W2364314275 hasConcept C150194340 @default.
• W2364314275 hasConcept C190727270 @default.
• W2364314275 hasConcept C2776283816 @default.
• W2364314275 hasConcept C2776694085 @default.
• W2364314275 hasConcept C2778461978 @default.
• W2364314275 hasConcept C2778729363 @default.
• W2364314275 hasConcept C2780007613 @default.
• W2364314275 hasConcept C2780235182 @default.
• W2364314275 hasConcept C2780817109 @default.
• W2364314275 hasConcept C30481170 @default.
• W2364314275 hasConcept C53226629 @default.
• W2364314275 hasConcept C55493867 @default.
• W2364314275 hasConcept C71924100 @default.
• W2364314275 hasConcept C86803240 @default.
• W2364314275 hasConcept C90924648 @default.
• W2364314275 hasConceptScore W2364314275C104317684 @default.
• W2364314275 hasConceptScore W2364314275C126322002 @default.
• W2364314275 hasConceptScore W2364314275C143998085 @default.
• W2364314275 hasConceptScore W2364314275C150194340 @default.
• W2364314275 hasConceptScore W2364314275C190727270 @default.
• W2364314275 hasConceptScore W2364314275C2776283816 @default.
• W2364314275 hasConceptScore W2364314275C2776694085 @default.
• W2364314275 hasConceptScore W2364314275C2778461978 @default.
• W2364314275 hasConceptScore W2364314275C2778729363 @default.
• W2364314275 hasConceptScore W2364314275C2780007613 @default.
• W2364314275 hasConceptScore W2364314275C2780235182 @default.
• W2364314275 hasConceptScore W2364314275C2780817109 @default.
• W2364314275 hasConceptScore W2364314275C30481170 @default.
• W2364314275 hasConceptScore W2364314275C53226629 @default.
• W2364314275 hasConceptScore W2364314275C55493867 @default.
• W2364314275 hasConceptScore W2364314275C71924100 @default.
• W2364314275 hasConceptScore W2364314275C86803240 @default.
• W2364314275 hasConceptScore W2364314275C90924648 @default.
• W2364314275 hasIssue "15" @default.
• W2364314275 hasLocation W23643142751 @default.
• W2364314275 hasLocation W23643142752 @default.
• W2364314275 hasOpenAccess W2364314275 @default.

• next